GHRYVELIN 60 mg, granules for oral suspension in a sachet sachet
Active ingredients: ACÉTATE DE MACIMORÉLINE, MACIMORÉLINE
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Granules for oral suspensionsachetorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- GHRYVELIN 60 mg granulés pour suspension buvable en sachet
- Pharmaceutical form
- granulés pour suspension buvable
- Route of administration
- orale
- Presentation description
- 1 sachet(s) polyéthylène basse densité (PEBD) aluminium papier de 1,817 mg
- Marketing authorisation holder
- ATNAHS PHARMA NETHERLANDS (PAYS-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 18 Feb 2025
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68930729CIP75508642CIP133400955086420Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MACIMORÉLINEgranulés | 60 mg · un sachet | FT |
| ACÉTATE DE MACIMORÉLINEgranulés | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.